Long-term safety of satralizumab in neuromyelitis optica spectrum disorder: results from the open-label extension periods of SAkuraSky and SAkuraStar

被引：0
|
作者：
Greenberg, B. M. [1 ]
de Seze, J. [2 ]
Saiz, A. [3 ,4 ]
Yamamura, T. [5 ]
Yeaman, M. [6 ]
Marcillat, C. [7 ]
Kou, X. [7 ]
Weber, K. [7 ]
Blondeau, K. [7 ]
Weinshenker, B. G. [8 ]
Patti, F. [9 ,10 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Hop Hautepierre, Strasbourg, France
[3] Hosp Clin Barcelona, Serv Neurol, Barcelona, Spain
[4] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[5] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo, Japan
[6] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Mayo Clin, Rochester, MN USA
[9] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy
[10] Multiple Sclerosis Ctr AOU Policlin G Rodolico Sa, Catania, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P023
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): Results from open-label extension periods of SAkuraSky and SAkuraStar
    Haskova, Zdenka
    Greenberg, Benjamin
    Bennett, Jeffrey
    Weinshenker, Brian G.
    Traboulsee, Anthony
    Yeaman, Michael R.
    Weber, Kristina
    Blondeau, Kathleen
    von Budingen, H-Christian
    Stokmaier, Daniela
    Klingelschmitt, Gaelle
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [2] Efficacy of satralizumab in neuromyelitis optica spectrum disorder (nmosd): results from open-label extension periods of sakurasky and sakurastar
    Greenberg, B.
    Bennett, J.
    De Seze, J.
    Kleiter, I.
    Szczechowski, L.
    Yamamura, T.
    Fox, E.
    Weinshenker, B.
    Von Buedingen, H. C.
    Stokmaier, D.
    Klingelschmitt, G.
    Weber, K.
    Costantino, C.
    Traboulsee, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 457 - 457
  • [3] Long-term efficacy of satralizumab in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the open-label extension periods of SAkuraSky and SAkuraStar
    Kleiter, I.
    Traboulsee, A.
    Palace, J.
    Yamamura, T.
    Fujihara, K.
    Saiz, A.
    von Budingen, H-C
    Stokmaier, D.
    Klingelschmitt, G.
    Bennett, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 148 - 149
  • [4] Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar
    Yamamura, Takashi
    Weinshenker, Brian
    Yeaman, Michael R.
    De Seze, Jerome
    Patti, Francesco
    Lobo, Patricia
    Von Buedingen, H-Christian
    Kou, Xiujing
    Weber, Kristina
    Greenberg, Benjamin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 66
  • [5] Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
    Kleiter, Ingo
    Traboulsee, Anthony
    Palace, Jacqueline
    Yamamura, Takashi
    Fujihara, Kazuo
    Saiz, Albert
    Javed, Adil
    Mayes, David
    von Buedingen, H-Christian
    Klingelschmitt, Gaelle
    Stokmaier, Daniela
    Bennett, Jeffrey L.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (01):
  • [6] Long-term Efficacy and Safety of Satralizumab in Adults with AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Roll-over, Open-label Study SAkuraMoon
    Bennett, J. L.
    Greenberg, B.
    Weinshenker, B. G.
    Traboulsee, A.
    Yeaman, M. R.
    Javed, A.
    Blondeau, K.
    Klingelschmitt, G.
    Marcillat, C.
    Gholizadeh, S.
    Vodopivec, I.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 168 - 169
  • [7] The N-MOmentum Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Long-term, Open-label Efficacy and Safety Update
    Cree, B. A.
    Bennett, J. L.
    Weinshenker, B. G.
    Wingerchuk, D.
    Paul, F.
    Kim, H.
    Pittock, S.
    Fujihara, K.
    Cutter, G.
    Marignier, R.
    Aktas, O.
    Hartung, H.
    Green, A. J.
    Drappa, J.
    She, D.
    Cimbora, D.
    Rees, W.
    Smith, M.
    Ratchford, J. N.
    Katz, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 83 - 83
  • [8] The N-MOmentum Trial Of Inebilizumab For Neuromyelitis Optica Spectrum Disorder: Randomized Controlled Period And Long-term Open-label Extension
    Cree, B. A.
    Bennett, J. L.
    Kim, H.
    Weinshenker, B.
    Pittock, S.
    Wingerchuk, D.
    Fujihara, K.
    Paul, F.
    Cutter, G.
    Marignier, R.
    Green, A.
    Aktas, O.
    Hartung, H.
    Lublin, F. D.
    Mealy, M. A.
    Drappa, J.
    Barron, G.
    Madani, S.
    She, D.
    Cimbora, D.
    Rees, W.
    Ratchford, J. N.
    Katz, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 10 - 11
  • [9] Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder
    Wingerchuk, D. M.
    Pittock, S. J.
    Berthele, A.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K-C.
    Allen, K.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 45 - 46
  • [10] Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Pittock, Sean J.
    Berthele, Achim
    Fujihara, Kazuo
    Kim, Ho Jin
    Levy, Michael
    Palace, Jacqueline
    Nakashima, Ichiro
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Allen, Kerstin
    Fujita, Kenji P.
    Yountz, Marcus
    Armstrong, Roisin
    NEUROLOGY, 2020, 94 (15)
12345